Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based CTO’ operating in the Biotechnology space. If you think a CTO’ is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Ben Mabey
CTO of Recursion Pharmaceuticals
Ben is passionate about Recursion’s mission of decoding biology to radically improve lives. Before joining Recursion Ben was a Data Scientist in the healthcare space applying biometric sensors in wellness and recovery programs. Prior to that he ran a data science consulting company and was a machine learning engineer in ad-tech. Ben earned his MS in Computer Science from the University of Utah where he studied computer graphics and machine learning. Outside of work Ben enjoys spending time with his wife and kids, trail running, and competing in triathlons.
Follow Ben Mabey:
About Recursion Pharmaceuticals: Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
_______
Richard Terry
CEO, CTO and Founder of Harton Therapeutics
For more than 15 years, Richard Terry has led cross-functional teams in the development of innovative and novel technologies. His unique background in aerospace engineering, physics and biochemistry is a testament to his ability to transcend barriers and bring together a diverse set of resources to achieve the impossible. Richard’s research interests include applying systems-level engineering to biological challenges, and he is a prominent expert in synthetic biology. Prior to launching ReadCoor, Richard was Lead Senior Staff Scientist at Harvard University’s Wyss Institute for Biologically Inspired Engineering. At the Wyss, he supported advancements in reading, writing and editing nucleic acid, better known as nucleic acid sequencing, gene synthesis, and gene editing. Richard was one of the institute’s first hires and joined the founding team before the research center opened its doors. He built and transformed the Synthetic Biology group from its earliest form into the world-renowned Translational Synthetic Biology group that it is today. A sample of the tools developed by the Synthetic Biology group under his charge includes Ultra-Long DNAs, Next Gen Sequencing, Nanopore Sequencing, Multiplexed Automated Genome Engineering (MAGE), Programmable DNA Nanotherapeutic Robotic Device, CRISPR, TALEN, Zinc Finger, CADnano, SeqTag, Data Encoding and Enzymatic Synthesis of DNA.
Follow Richard Terry:
About Harton Therapeutics, Harvard Medical School: Harton is a biotechnology platform company pioneering the next revolution in personalized immune therapies to treat each and every patient.
Joshua Nixon
CTO and Co-Founder of Prime Roots
Follow Joshua Nixon:
About Prime Roots: Prime Roots is celebrating the culture of meat by reimagining protein itself.
Herb Yoo
Co-Founder, CTO of Senaptec
Herb has extensive experience in the innovation and delivery of sensory performance products and services. While working for Nike, he created sensory assessment and treatment tools resulting in over 25 patents and directed the sensory research program that led to collaboration and published work with research universities. He also provided sensory performance training directly to professional sports teams, college athletic programs, and special operations units in the US military. Herb also spent 8 years in the Nike Sport Research Lab, conducting performance product research and conceptualizing athlete performance evaluation services. He completed both undergraduate work and Masters degree at the University of Michigan in the College of Engineering where he studied human factors and biomechanics. During his graduate school years, he conducted research on the visual demand and impact of in-vehicle systems on driving performance at the University of Michigan Transportation Research Institute. Herb lives near Portland, Oregon with his wife Christine and two children.
Follow Herb Yoo:
About Senaptec: Senaptec is developing a portfolio of tools to assess and improve brain health and performance.
Bryan Lynch
Chief Technology Officer of ReliantHeart
Mr. Lynch is the Chief Technology Officer, VP of Worldwide Sales and Co-Founder of ReliantHeart. Mr. Lynch is one of the principle designers of the HA5 LVAD system including the compelling new wireless remote monitoring technology embedded in the new controller. Mr. Lynch began working on the NASA blood pump in 1997. Previously, he served as director of marketing and product development with Komet Medical Inc., a German maker of surgical instruments and hard tissue cutting systems. From 1990 to 1994, he served as manager of engineering, research and development for Surgimedics Inc., a Texas-based medical device company, developing products for minimally invasive surgery, laser surgery, and autologous blood transfusion. He is the inventor and co-inventor of several patents, including catheter access, pulsatile loop and implantable pump patents.
Follow Bryan Lynch:
About Explorer Aircraft, ReliantHeart: ReliantHeart, Inc. is a leading innovator in mechanical circulatory support therapies for advanced stage heart failure.
Brett Goldsmith
Chief Technology Officer of Cardea Bio
A founding member of Nanomed and the company’s CTO, Dr. Goldsmith’s passion is taking nanoelectronic technology out of the theoretical realm to create practical and manufacturable products that better people’s lives. One of the few people in the world with the combined expertise in biology and nanotechnology needed to develop graphene as a viable bio-electronic device, Dr. Goldsmith was the lead researcher on landmark academic papers in Science and Nature Nanotechnology demonstrating the coupling of biochemical systems to carbon nanotubes, for which he won the Nottingham Prize from the Physics Electronics Conference. Following graduate school at UC Irvine, Dr. Goldsmith joined the University of Pennsylvania as an Intelligence Community Fellow and led a project developing nanoelectronic sensing of Lyme biomarkers as well as successfully integrated membrane proteins with nanoelectronic circuits. Leaving his post-doc position to start a nanotechnology group at the Navy’s San Diego laboratory, Dr. Goldsmith identified technological needs in the field and advanced nanotechnology solutions to those needs through partnership with programs including Living Foundries and IVN Dx. Prior to founding Nanomed, Dr. Goldsmith was the CTO of Nanosense in Mountain View where he developed and drove the first successful fabrication of a nanoelectronic sensing system in the chemical manufacturing industry in the form of commercial industrial gas sensors. Dr. Goldsmith brings proven experience in transforming academic learnings into viable commercial fabrications to his role as CTO of Nanomed.
Follow Brett Goldsmith:
About Cardea Bio, Nanomed: Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors.
Alex Aravanis
Chief Technology Officer & Senior Vice President of Illumina
Follow Alex Aravanis:
About Illumina: Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Chiu Chau
Co-Founder, CTO of OpenTrons
Chiu worked in biotech for 20+ years before building the first OpenTrons robot. In his previous company (bought by Immucor in 2008) he led the engineering team to build the core multiplex qPCR automation technology now used in most blood banks for advanced blood typing. Chiu grew up in Hong Kong and is a diehard raquetball player.
Follow Chiu Chau:
About OpenTrons: OpenTrons is a developer of a pipetting robot technology designed to automate experiments.
David Tsao
CTO of BillionToOne
David leads development of BillionToOne’s bioinformatics pipeline and is the source behind many of the technological developments at BillionToOne. He has a PhD in Bioengineering from Rice University. Before his PhD, he was a software engineer at Adku and Groupon, where he leveraged big data to build recommendation engines and search engine marketing solutions. David earned an AB in Physics from Princeton University. When not coding or pipetting, he enjoys rock climbing, backpacking, and pursuing the perfect cup of coffee.
Follow David Tsao:
About BillionToOne: BillionToOne is a precision diagnostics company that makes molecular diagnostics accurate, efficient, and accessible for all.
Craig Muir
Partner and Chief Technology Officer of Third Rock Ventures
Craig Muir brings to the company more than 25 years of technology development, implementation and application experience across the biotechnology and pharmaceutical industries. As a Partner and Chief Technology Officer at Third Rock Ventures, Muir leads the identification and integration of drug discovery and development technology platforms for companies across Third Rock’s portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes to scientific diligence for investment opportunities. Muir has been instrumental in expanding Third Rock’s San Francisco presence to increase access to innovative technologies and support its West Coast companies. He also assumes leadership roles in several of Third Rock’s portfolio companies, serving as Interim Chief Technology Officer or Information Officer through the first 12–18 months after launch. Prior to Third Rock, Muir served as Senior Vice President of Technical Operations for Codon Devices. Before that, he spent 12 years at Millennium Pharmaceuticals as Vice President of Platform Technology, where his teams were instrumental in raising $1.8 billion from pharmaceutical partners. Earlier in his career, he served in a number of technology development and scientific roles at Genentech, Tularik and the University of Vermont. Muir serves on the Scientific Advisory Board of the Bigelow Laboratory for Ocean Sciences. Muir completed his B.S. in animal physiology at the University of California, Davis and is a pioneer in the fields of laboratory automation and technology in biotech and pharmaceutical applications.
Follow Craig Muir:
About Global Blood Therapeutics, Pliant Therapeutics, Third Rock Ventures, Third Rock Ventures: Third Rock Ventures invests in transformational life science companies that show high growth potential
Aditya Rajagopal
Co-Founder & CTO of ChromaCode
Aditya Rajagopal is the Founder & CTO of ChromaCode, Inc, and a Visiting Associate in Electrical Engineering at Caltech. He completed his education at Caltech (B.S., M.S., and Ph.D.) and has fifteen years of experience in medical engineering, microfluidics, nanotechnology and bioengineering. Aditya Rajagopal’s research has resulted in innovative technology developments and he has authored over 50 patents and publications. He is the recipient of numerous honors including the Caltech Grubstake Award in 2017 and the Caltech Innovation Initiative (CI2) in 2014 and 2015.
Follow Aditya Rajagopal:
About ChromaCode: ChromaCode is a molecular diagnostics company focusing on bioinformatics.
Aditya Khosla
Co-founder & CTO of PathAI
Aditya recently completed his PhD in machine learning and computer vision at MIT. He completed his MS at Stanford in 2011 and BS at Caltech in 2009. In his research he developed new methods for an array of applications in computer vision, including eye-tracking, prediction of image memorability, and visualization of deep networks. He is the recipient of a Facebook Fellowship and his work has been widely covered by various media outlets including BBC, The New York Times and The Washington Post. He has published over 30 papers in the fields of deep learning, computer vision and neuroscience.
Follow Aditya Khosla:
About PathAI: PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time.
Landy Toth
CEO, Founder & CTO of LifeLens Technology
Follow Landy Toth:
About Autonomix Medical, DavosPharma, LifeLens Technology: LifeLens Technology is a biotechnology company that leads in innovative next generation treatment devices for personal health monitoring.
Sean Hunt
Co-founder & CTO of Solugen
Sean’s background in chemical engineering and chemistry led him to pursue his PhD at MIT on sustainable solutions to green chemicals. After hearing about Gaurab’s plant-based hydrogen peroxide discovery, Sean developed a method to make it at scale in an environmentally conscious way using one ingredient—plant starch. That’s when Bioperoxide was born.
Follow Sean Hunt:
About Solugen: Solugen is a specialty chemicals manufacturer creating chemistries that are safe, cost-effective, and environmentally-friendly.
Jeffrey Kaditz
Founder, CEO & CTO of Q Bio
Jeffrey Kaditz is a serial entrepreneur, angel investor and advisor who has helped drive a wide range of technologies and businesses. His fields of exploration have included rockets, high-energy particle physics, anti-ICBM technologies, consumer electronics, mobile gaming, finance, enterprise software, network security, and biotechnology. In 2012, he co-founded a leading fintech company, Affirm, with Manny Arias and they were later joined full-time by Nathan Gettings (Palantir co-founder) and Affirm’s first Angel Investor, Max Levchin (PayPal co-founder). Prior to Affirm he served as Chief Data & Analytics Officer at mobile gaming giant ngmoco which was acquired by DeNA. Jeffrey has degrees in Physics and Computer Science from Carnegie Mellon University.
Follow Jeffrey Kaditz:
About Q Bio: On a mission to build the first Clinical Digital Twin Platform and make it accessible to everyone
Troy Astorino
Co-Founder & CTO of PicnicHealth
Follow Troy Astorino:
About PicnicHealth: PicnicHealth helps patients easily access their medical records and gives them the opportunity to contribute data to medical research.
Jerry Bryant
Founder, Managing Member & CTO of Cell Point
Jerry Bryant, Jr., is a founding member of Cell>Point, the CTO and has been providing financial support to the company since its beginning. Mr. Bryant is also President and Managing Member of Vyripharm Biopharmaceuticals, a majority owned subsidiary of Cell>Point. Mr. Bryant brings 15 years in research experience in molecular biology, imaging and oncology. Prior to the establishment of Cell>Point, Mr. Bryant worked as a research assistant from 1994 through 1999 in the Department of Medicine, Division of Molecular Pathology, The University of Texas M.D. Anderson Cancer Center. During 1999 and 2000, Mr. Bryant served as President of Allcure JEMA, Inc. Mr. Bryant received his B.S. from Tennessee State University in 1987 and M.S. from the University of Florida in 1991.
Follow Jerry Bryant:
About Cell Point: Cell Point is a biotechnology company developing universal molecular imaging agents and intra-nuclear metallic therapeutics.
Ehud Pardo
CTO of Bioz
The CTO has over many years of experience in the software industry; co-founder of a SaaS platform that was acquired by Microsoft. He spent 6 years at Microsoft as bCentral development manager & senior developer of Dynamics CRM, and lately as architect and software developer at Liquid Robotics
Follow Ehud Pardo:
About Bioz: Bioz is a disruptive startup at the intersection of information technology and scientific research.
Yong Dai
Chief Technology Officer of Prevail Therapeutics
Yong Dai has served as our Chief Technology Officer since 2019. He joined Prevail in 2018 as the Senior Vice President of Gene Therapy, bringing more than 17 years of biotechnology industry experience focused on bioprocess development, chemistry, manufacturing and controls (CMC), good manufacturing practice (GMP), process validation, and regulatory submissions, including extensive work with gene therapy drug development. Prior to joining Prevail, Yong was the Senior Director of Process Development at uniQure, where he was responsible for process and analytical development and manufacturing sciences for early and late stage gene therapy drug development programs. Prior to his time at uniQure, he served as the Head of Process Development Commercial Support at Shire Pharmaceuticals and held senior CMC roles at ImmunoGen. Yong completed his postdoctoral research at Harvard University, and holds a Ph.D. in biochemistry and molecular biology from the Chinese Academy of Sciences. He also holds an M.S. in biochemistry and molecular biology and a B.S. in biochemistry from the Peking University in China.
Follow Yong Dai:
About Prevail Therapeutics: Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
Thrasyvoulos Karydis
CTO and Co-Founder of DeepCure
Thrasyvoulos Karydis is the CTO and Co-Founder at DeepCure.
Follow Thrasyvoulos Karydis:
About DeepCure: DeepCuris builds an AI engine for small-molecule drug discovery.
Pat Lorton
CTO of Schrödinger
Follow Pat Lorton:
About Schrödinger: Schrödinger develops a chemical simulation software for use in pharmaceutical and biotechnology research.
Alison Fleming
EVP ,Product Development & Chief Technology Officer of Collegium Pharmaceutical
Alison Fleming was appointed Chief Technology Officer in 2017. Alison Fleming first joined Collegium Pharmaceutical in 2002, shortly after completing her Ph.D. in the School of Chemical and Biomolecular Engineering at Cornell University. Prior to joining Collegium, her academic research focused on implantable drug delivery systems for cancer therapy. Alison Fleming is an inventor on several United States Patents and pending patent applications and has authored numerous scientific publications and poster presentations in the field of novel drug delivery systems. In 2001 she was the recipient of the Jorge Heller Journal of Controlled Release Outstanding Paper Award. She received her B.S. degree in Chemical Engineering from the University of Massachusetts, Amherst.
Follow Alison Fleming:
About Collegium Pharmaceutical: Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Rob High
IBM Fellow, VP, CTO IBM Edge Computing of IBM Research
Rob High is an IBM Fellow, Vice President and Chief Technology Officer, IBM Watson. He has overall responsibility to drive Watson technical strategy and thought leadership. As a key member of the Watson Leadership team, Rob works collaboratively with the Watson engineering, research, and development teams across IBM. Prior to joining the Watson team, Rob was Chief Architect for the SOA Foundation and member of the IBM Academy of Technology, Rob championed an open industry architectural definition of the principles of business and IT alignment enabled by SOA and Business Process Optimization, as well as ensuring IBM’s software and services portfolio is architecturally grounded to enable for efficient SOA-based solutions. This responsibility extended across the IBM software portfolio, including WebSphere, Rational, Tivoli, Lotus, and Information Management offerings. Rob has 37 years of programming experience and has worked with distributed, object oriented, component-based transaction monitors for the last 26 years, including SOMObject Server, Component Broker, and the WebSphere Application Server. Rob previously served as Chief Architect for the WebSphere foundation with architectural responsibility for the WebSphere Application Server and the related products integrated on that core runtime.
Follow Rob High:
About IBM Research: IBM Research provides research and developments related to the technological industry.
Anna Topol
Chief Technology Officer Gloabl Think Labs, IBM Industry Research of IBM Research
Chief Technology Officer in Industry & Solutions Group at IBM Research. Develops technical offerings, strategy & geo-specific tactics to help clients transform their businesses. Previously a CTO in Systems Group responsible for technical enablement & communications for Distribution and Telecommunication Sector in the area of Cloud, Analytics, Security and Technical Computing. Developed Industry-specific value propositions of IBM’s servers, storage & networking equipment and its integration with software and service offerings. Chair of IEEE Women in Engineering Schenectady NY Chapter (2015), Recognized by Continental Who†s Who in the field of Information Technology (2014), and National Association of Professional Women (NAPW) as VIP Woman of The Year (2014); IBM Distinguished Engineer and Master Inventor; Member of IBM Academy of Technology. With 15+ years of experience in both technical & business development positions and lead roles in strategic R&D outlooks, Intellectual Property Management, and R&D. 80+ Publications, 3 Book Chapters, 43 Patents. Focused on technical vitality, building positive culture, trust and commitment.
Follow Anna Topol:
About IBM Research: IBM Research provides research and developments related to the technological industry.
Ming Yan
Co-Founder and CTO of Cytek Biosciences
Ming Yan is a co-founder of Cytek Biosciences, Inc. with over 20 years of R&D experience in leadership and innovation. Prior to Cytek, Ming Yan held research and development positions at AT&T Bell Laboratories, Lawrence Livermore National Labs and BD Biosciences. He is one of the thought-leaders in flow cytometry instrumentation and standardization. Ming Yan has published several research papers relating to laser spectroscopy and cell analysis in top peer-reviewed journals. He has over a dozen patents and patent pending applications for his innovations.
Follow Ming Yan:
About Cytek Biosciences: Cytek Biosciences is a manufacturer and supplier of flow cytometry products and services.
Aaron Kimball
CTO of Zymergen
At Zymergen, Aaron is responsible for building the data architecture to facilitate a robotics-driven approach to genome engineering. Prior to joining Zymergen, Aaron has worked at several big data-oriented startups. He was the first employee at Cloudera, where he helped with a variety of big data challenges. In 2010 Aaron cofounded WibiData, the big data application company. Aaron has been working with the open-source project Apache Hadoop since 2007 and authored Apache Sqoop and MRUnit. He holds a bachelor’s degree from Cornell University and a master’s degree from the University of Washington in computer science.
Follow Aaron Kimball:
About Zymergen: Zymergen is a biotechnology company that specializes in machine learning, big data, and artificial intelligence.
James H. Bullard
Co-Founder and CTO of Pendulum Therapeutics
James Bullard is a Computational Biologist and Biostatistician with extensive experience in analyzing complex genomic systems. Prior to co-founding Whole Biome, Jim served as a Senior Staff Scientist at Pacific Biosciences. Jim, completed his Ph.D. in Biostatistics with a focus in Computational and Genomic Biology at the University of California, Berkeley and his B.A. in Computing and Information Systems at Northwestern University.
Follow James H. Bullard:
About Pendulum Therapeutics: Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
Linhao Zhang
CTO and Co-Founder of TrialSpark
Follow Linhao Zhang:
About TrialSpark: TrialSpark is a technology company that helps bring treatments to patients faster by reimagining how clinical trials are run.
Debkishore Mitra
Co-founder & Chief Technology Officer of Lucira Health
Follow Debkishore Mitra:
About Lucira Health: Lucira Health is a biotechnology company that offers disposable test kits to detect RNA and DNA of infectious diseases.
Philip Ross
CTO of MycoWorks
Follow Philip Ross:
About MycoWorks, Stanford University: MycoWorks is a biotech company that delivers commercially viable non-plastic and non-animal materials to the market.
Anju Nagpal
DIRECTOR – R&D FINANCE of Biogen Idec
Finance professional with over 20 years of experience across financial planning, accounting, financial reporting and strategy business analysis in the life sciences and high-tech industries. Currently works at Biogen as Director, R&D Finance. Held financial management positions of increasing responsibility that involve broad-based responsibilities to provide critical support and leadership to various aspects of the business. Possesses strong skills in finance, business processes and related systems to drive an efficient and effective finance function. Proven track record of implementing planning, accounting and analysis tools to aid business growth, decision making and achievement of financial commitments. Operates as a credible business partner who influences decision making to build and retain shareholder value.
Follow Anju Nagpal:
About Biogen Idec, Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Luis F Voloch
Chief Technology Officer and Co-founder of Immunai
Follow Luis F Voloch:
About Immunai: Immunai is a biotech company that combines single cell genomics with ML algorithms to enable high resolution profiling of the immune system.
Matthew Hayes
CTO of evonetix
Matthew Hayes is the Interim CEO and CTO at Evonetix.
Follow Matthew Hayes:
About evonetix: Evonetix is a provider of a desktop platform designed to synthesize DNA at unprecedented accuracy and scale.
Roman Yelensky
EVP & CTO of Gritstone Oncology
Roman Yelensky is responsible for overseeing Gritstone’s genomics, proteomics and informatics programs. Previously, he was vice president of biomarker and companion diagnostic development at Foundation Medicine. While there, he co-led sequence data analysis for FoundationOne™ and led validation studies supporting clinical laboratory accreditation and testing of more than 100,000 patients. Roman Yelensky established Foundation Medicine’s FDA-regulated products program, leading to the FDA approval of FoundationFocusCDxBRCA, the first NGS-based companion diagnostic. He also contributed to key national initiatives on the clinical implementation of next-generation sequencing (NGS), leading the diagnostic implementation of Lung-MAP, a first-of-its-kind NCI-sponsored trial matching lung cancer patients to investigational treatments using comprehensive genomic testing. Prior to Foundation Medicine, Roman Yelensky was a senior scientist in biomarker development at Novartis. He has co-authored more than 75 manuscripts on bioinformatics, statistical genetics, NGS biomarker and assay development and cancer genomics. He is an alumnus of Stanford University and the Harvard-MIT Division of Health Sciences and Technology.
Follow Roman Yelensky:
About Gritstone Oncology: Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Paul Hindrichs
Co-Founder, CTO of Conventus Orthopaedics
Paul Hindrichs is a veteran business leader and innovator with more than 20 years of medical device experience. He has served in various management capacities during his career, including positions with several other start-up and early stage medical device companies. Prior to founding Conventus, he worked for St. Jude Medical (SJM), Vascular Science, Inc., Optical Sensors, Inc., and Schneider USA (Pfizer). Most recently, he was responsible for the Structural Heart Business and Cardiac Technologies Group at SJM. Mr. Hindrichs earned a Bachelor of Science in Mechanical Engineering from the University of Minnesota and is a named inventor on 20 issued and 22 pending patent applications.
Follow Paul Hindrichs:
About Conventus Orthopaedics, Endogenex: Conventus Orthopaedics is a provider of a range of orthopedic and sports medicine services.
Giulio Ruffini
President, CSO and co-founder of Neuroelectrics
Dr. Giulio Ruffini is the CEO and CTO of Starlab and the president and CSO of Neuroelectrics. He obtained a BA in Mathematics & Physics from Berkeley and a PhD in theoretical physics from UC Davis/LANL in 1995. In 2000 he founded Starlab to transform science into high-impact technologies.
12 years later he founded Neuroelectrics, a company which combines high-precision multichannel stimulation technologies with advanced biophysical and neuro-computational models.
For the past 15 years, Giulio has been developing technology for and researching the use of non-invasive brain monitoring and brain stimulation techniques, with a focus on EEG and transcranial current stimulation. His paper on brain-to-brain telepathy communication was the top 10 most shared papers of 2014. He is currently leading or involved in several European programs such as Galvani ERC Synergy, STIPED or Neurotwin.
Follow Giulio Ruffini:
About Neuroelectrics: Neuroelectrics is a digital brain health company that diagnoses and treats brain disorders with personalized neuromodulation, and improves overall brain health.
Sharat Israni
Exec Dir & CTO, Bakar Computational Health Sci Institute of University of California, San Francisco
Sharat Israni is the Exec Dir & CTO, Bakar Computational Health Sci Institute at UCSF.
Follow Sharat Israni:
About University of California, San Francisco: Director of the Lab for Advanced Cytometry (LAC) and the Sony Biotechnology Center at UCSF in the Department of Laboratory Medicine
Chas Andre
CTO & Head of I.P. and Instrumentation of Depixus
Chas has over 17 years of experience successfully bringing life science tools to market with companies such as Applied Biosystems, MJ Research; BioRad, and Thermo Fisher Scientific. He graduated from The University of Chicago with a bachelor’s degree in biology, and earned a Ph.D. in Genetics from Stanford University. He has overseen the launch of dozens of products in the PCR, qPCR and DNA sequencing sectors, including instruments, consumables, and software, with a particular focus on applications and system integration.
Follow Chas Andre:
About Depixus: Depixus are pioneering the development of MAGNA, a novel genetic analysis technology for decoding the dynamic genome.
Shane Colley
CTO of Tempus
Shane Colley is the Chief Technology Officer at Tempus. Prior to joining Tempus, Colley was Vice President of Research and Development at R1 RCM (formerly Accretive Health), where he built and led a global organization of over 200 product, architecture, design, and development professionals that were responsible for R1’s technology portfolio. Colley earned his Bachelor of Science in Computer Science from Iowa State University.
Follow Shane Colley:
About Tempus: Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.
Peter Licari
CTO of Eat Just
Follow Peter Licari:
About Eat Just: Eat Just offers a plant-based egg substitute intended to provide healthy and nutritional food alternatives.
Charles A. Taylor
Founder and Chief Technology Officer of HeartFlow
Charles Taylor is a co-founder, Chief Technology Officer (CTO), and member of the Board of Directors of HeartFlow Inc. Previously, he was an Associate Professor in the Department of Bioengineering and Surgery at Stanford University with courtesy faculty appointments in the Departments of Mechanical Engineering and Radiology. He is internationally recognized for the development of computer modeling and imaging techniques for cardiovascular disease research, device design and treatment planning. He received his B.S. degree in Mechanical Engineering, M.S. degree in Mechanical Engineering and M.S. degree in Mathematics from Rensselaer Polytechnic Institute and a Ph.D. in Mechanical Engineering from Stanford University.
Follow Charles A. Taylor:
About HeartFlow: HeartFlow is a medical technology company that provides new methods of diagnosis and treatment of cardiovascular disease.
Konstantin Konstantinov
Chief Technology Officer of Codiak Biosciences
Follow Konstantin Konstantinov:
About Codiak Biosciences, Codiak Biosciences: Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
Irene Bosch
Co-founder & CTO of E25Bio
Irene Bosch serves as the CEO and founder of E25Bio.
Follow Irene Bosch:
About E25Bio: E25Bio specializes in the development of rapid diagnostic tests for epidemic fever viruses.
Lee Chae
Co-Founder and CTO of Brightseed
Lee Chae is the Co-founder and CTO at Brightseed.
Follow Lee Chae:
About Brightseed: Brightseed features artificial intelligence that reveals powerful compounds hidden in nature.
Michael Hoey
Co-Founder, Chief Technology Officer & Board of Directors of NxThera
Michael Hoey is the Founder and CTO of NxThera.
Follow Michael Hoey:
About Francis Medical, NxThera: NxThera develops medical technologies to treat a variety of endourology conditions, including BPH.
Tom Lowery
Chief Technology Officer of Satellite Bio
Tom Lowery is the Chief Technology Officer at Satellite Bio.
Follow Tom Lowery:
About Satellite Bio: Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering.
Penjit Moorhead
Co-Founder and CTO of Arine
Follow Penjit Moorhead:
About Arine: Arine optimizes medications and improves human health through data-driven clinical services.
Peter Meinhold
Co-Founder & CTO of Provivi
Mr. Peter Meinhold, Ph.D., serves as Chief Technology Officer of Provivi, Inc. Mr. Meinhold was a co-founder and Director of Research at Gevo, Inc. since 2005 until May 2013. He has 12 years of experience in research and development of biotechnology for fuels and chemicals production. For his thesis research, Mr. Meinhold engineered the fatty acid hydroxylating cytochrome P450 BM-3 into an alkane hydroxylating one that accepts substrates as short as ethane. In 2010, he was recognized by MIT’s Technology Review magazine as one of the world’s top innovators. He holds nine issued patents in the U.S. alone with dozens more pending. Mr. Meinhold received his Diploma (equivalent to a B.Sc.) in Biotechnology from the University of Applied Sciences Weihenstephan, Germany and a PhD in Biochemistry at the California Institute of Technology.
Follow Peter Meinhold:
About Provivi: Provivi develops biopesticides for agriculture, commercial, household, and public health pest management.
Christian Foster
Co-Founder & CTO of Ligandal
Follow Christian Foster:
About Ligandal: Ligandal is creating cell-specific delivery systems for gene editing tools such as CRISPR using automation and peptide-based nanoparticles.
Andrew J. Buckler
President and CTO of Elucid
Andrew Buckler comes to Elucid Bioimaging with 30 years of industry R&D experience spanning imaging science, medical devices, and molecular medicine. He founded Elucid’s predecessor company BBMSC and co-founded vascuVis. with Philips, Agilent, HP, Siemens, and Eastman Kodak. Andrew Buckler has developed a number of quantitative imaging products, including a program that netted $100M new revenue in its first year, with a life cycle > 7 years and with spin offs touching all parts of a $1B annual imaging business, and holds 9 patents. He is also the originator of an in-vivo imaging hardware and software molecular medicine product for research applications in disease management and drug discovery. Andrew Buckler has served as Program Director for the Quantitative Imaging Biomarker Alliance (QIBA) since its inception, is presently a scientific advisor to the Foundation for the National Institutes of Health (FNIH) for regulatory decision making in clinical trials, and has served as Subject Matter Expert in imaging for both radiology and pathology informatics to the NCI, and Principal Investigator (PI) for grant programs from NSF in computer-aided prognostics and from NIST for the pursuit of informatics services for statistically valid and clinically meaningful development and performance assessment of quantitative imaging biomarkers. Andrew Buckler holds a certificate in “Leading Science-Based Enterprises” from Harvard Business School, an MSCS from the University of Rochester, and a BSEE from Lehigh University.
Follow Andrew J. Buckler:
About Elucid: Elucid improves accuracy, experience, and cost-effectiveness of cardiovascular diagnostic imaging.
Matthew Ball
CTO of Culture Biosciences
Matthew Ball is a Co-Founder and Chief Technology Officer at Culture Biosciences.
Follow Matthew Ball:
About Culture Biosciences: Culture Biosciences develops automated bio-reactors that help companies optimize their manufacturing processes.
Scott Tudman
CTO of Sweetwater Energy
Scott Tudman currently works as Chief Technology Officer at Sweetwater Energy.
Follow Scott Tudman:
About Sweetwater Energy: Sweetwater Energy is a company that produces concentrated sugar from multiple non-food plant materials.
Erik Gentalen
CTO & Co-founder of Intabio
Erik is the inventor of Intabio’s microfluidic-based innovations, and is responsible for advancing the technology and the overall development of the BlazeTM system. Erik has spent over 16 years developing microfluidic tools for the analysis of proteins and nucleic acids. Prior to Intabio, Erik was the Director of Systems Integration at ProteinSimple where he led the R&D team developing the Simple Western capillary immunoassay from invention to launch, and also led product support for the iCE3 capillary-based IEF system. Prior to ProteinSimple, he was the Program Manager at Caliper Life Sciences, where he led the system integration for a microfluidic research system, developed chip designs for customer applications, and managed application development collaborations with pharmaceutical partners. Erik was also an early employee at Affymetrix and Combimatrix, where his responsibilities included designing instrumentation, developing synthesis methods, managing the DNA array production facility, and collaborating on novel array applications. Erik is also a registered patent agent.
Follow Erik Gentalen:
About Intabio: Intabio is a developer of a real-time protein analytics platform used to transform the development of biotherapeutic drug.
Pep Gubau
Executive Chairman, CTO & Co-Founder of Aizon
Pep is an IT entrepreneur and has been working in IT for the last 25 years, being pioneer in Linux adoption in the 90s, cloud in the 2000s and big data in the last years. Although having a theoretical economics and maths profile, his early career was as a software developer for the chemical industry. He later was CTO & COO of an IT consulting firm, leading a team of more than 200 engineers until 2003 when Pep created his first IT company with a clear core principle: customer centric focus. Two more followed. In 2013 Pep started thinking on the next thing to work on. bigfinite is the result of this initial spark that immediately caught fire in Pere and Toni. Pep is Economist (University of Barcelona) with an engineering background.
Follow Pep Gubau:
About Aizon: Aizon is a cloud-based SaaS platform that helps optimize industrial processes in biotech and pharma.
Sergio Aguirre Valencia
Founder & CTO of EchoPixel
A pioneer in stereoscopic 3D systems, Aguirre has over 15 years of experience in visualization systems. Prior to forming EchoPixel, Aguirre developed one of the first stereoscopic 3D video systems. Aguirre is responsible for leading technological development at EchoPixel as they continue to partner with leading luminary sites.
Follow Sergio Aguirre Valencia:
About EchoPixel: EchoPixel develops medical imaging devices that enable doctors to use CT images of a patient’s abdomen and display a 3D model.
Stephen Turner
CTO of Pacific Biosciences
Dr. Turner founded Pacific Biosciences (formerly Nanofluidics) and secured its Series A funding in 2004. He was awarded a Ph.D. in Physics by Cornell University in 2000, where he worked with Prof. Harold Craighead to study the behavior of biomolecules in nano-fabricated structures. His work contributed to the establishment of the Nanotechnology Center at Cornell. He was a member of the project team at Cornell which developed the technology now employed by Pacific Biosciences and was co-author of the cover story in Science magazine (January 31, 2003) that introduced the technology to the scientific community. Dr. Turner’s undergraduate work was at the University of Wisconsin, Madison, where he received a Bachelor of Science in Applied Mathematics, Electrical Engineering and Physics. He is the author of over 30 scientific papers in fields ranging from nanofluidics, genetics, cell attachment to chemically- and topographically- modified surfaces, x-ray lithography and process modeling. He is listed as the inventor on nine U.S. patents and more than 20 published patent applications. Dr. Turner was recipient of the MIT Technology Review “TR100” Award in 2003 and the University of Wisconsin Madison Distinguished Young Alumnus Award in 2008. He is a sitting member of the National Institutes of Health grant review study section on new technologies. He oversees the scientific and technical direction of Pacific Biosciences.
Follow Stephen Turner:
About InVivo Biosystems, Pacific Biosciences: Pacific Biosciences designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
Nigel P. Beard
CTO of Encodia
Nigel P. Beard is the Chief Technology Officer (CTO) of Encodia.
Follow Nigel P. Beard:
About Encodia: Encodia is a biotech company that develops the next generation of protein analysis tools.
Michael Hanson
Chief Technology Officer of ShouTi
Michael Hanson is the Chief Technology Officer at ShouTi.
Follow Michael Hanson:
About ShouTi: ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR.
Ian Maurer
Chief Technology Officer of GenomOncology
Follow Ian Maurer:
About GenomOncology: GenomOncology enables precision medicine by translating next generation sequencing data into actionable information.
Ian Maurer
Chief Technology Officer of GenomOncology
Follow Ian Maurer:
About GenomOncology: GenomOncology enables precision medicine by translating next generation sequencing data into actionable information.
Scott Ruston
CTO of Ichor Therapeutics
Follow Scott Ruston:
About Ichor Therapeutics: Ichor Therapeutics develops and commercializes research and clinical products in the field of regenerative medicine.
Jeffrey Schell
Managing Director, CTO, Patent Attorney of Proov
Jeff’s mission is to transform innovative concepts into companies. In 2015, Jeff leveraged the valuable IP that he cultivated and developed to raise three million dollars in debt financing to acquire medical device company TranS1’s assets out of a failed merger. Within a few years of rebuilding TranS1 as CEO, ColoradoBiz Magazine named TranS1 one of the top 250 companies in Colorado by revenue. The Denver Post also named TranS1 Denver’s “Most Innovative Workplace” in 2016. Further, the Colorado Technology Association named TranS1 a nominee for “Company of the Year.” Under Jeff’s leadership, Orthopedics This Week awarded TranS1 with the 2017 Spine Technology Award. In 2018, Jeff had a successful exit from TranS1. In 2018, Jeff took a significant stake in Proov – evolving its underlying tech into multiple patent pending products and an emerging brand in women’s health – and he continues to play a leadership role. Soon thereafter, the company was featured in Forbes and won the “Best Family Tech at CES” award given by Parents Magazine. In 2019, the company won SXSW Startup of the Year. In 2020, the company raised several million dollars in VC and grant funding, gained distribution at leading retailers, won the coveted “Colorado Companies to Watch” recognition, and in 2021 grew to become named as one of the Denver Business Journal’s “25 largest biotechnology companies in Colorado.” Proov closed a $10MM Series A with the involvement of multiple prominent venture capital firms in 2021. In 2019, top tier law firm Hall Estill acquired the rights to the Rocky Mountain Patent brand. Jeff now leads the Ventures Growth practice for Hall Estill. In addition to building intellectual property strategies with the Rocky Mountain Patent team, Jeff now advises, operates and invests in multiple companies. Jeff is the former President of TiE Denver and remains heavily engaged with investment and startup advisory groups including Rockies Venture Club, BoomTown, TechStars and Prime Health. Jeff attended Northwestern University, graduating with degrees in Industrial Engineering & Management Sciences and Economics in 2004. He subsequently earned his JD and masters degrees in International Studies and Medical Informatics. Jeff separately studied economics at Harvard University, and in 2007, was a delegate at the Harvard China-India Development & Relations Symposium. ColoradoBiz Magazine named Jeff one of the 25 “Most Influential Young Professionals in Colorado” and he is a “40 under 40” honoree. He was also a finalist for the Denver Post’s “Colorado Innovator of the Year” and “Denver Trailblazer” awards. In 2017, Denver Mayor Michael Hancock invited Jeff to participate in Denver’s official trade delegation to South Africa and Kenya.
Follow Jeffrey Schell:
About MindMiner, Proov, Rocky Mountain Patent: Proov offers the most advanced system for women to evaluate their hormones at home, built upon patented, FDA cleared medical devices.
Andy Zitney
SVP & CTO of McKesson
Follow Andy Zitney:
About McKesson: McKesson distributes medical supplies, information technology, and care management products and services.
Kathy McElligott
Executive Vice President, Chief Information Officer and Chief Technology Officer of McKesson
Kathy McElligott is Executive Vice President, Chief Information Officer and Chief Technology Officer of McKesson Corporation. As CIO, McElligott is responsible for all technology initiatives within the corporation. As CTO, McElligott guides the overall technology direction for the company’s healthcare technology products, and provides support and guidance for application development processes companywide. Prior to McKesson, McElligott served as the CIO of Emerson, a St. Louis-based global manufacturing and technology company, where she managed the company’s information technology strategy and information security for its global operations, including hardware, software, and services, as well as its telecommunications and data center infrastructure. In her 15 years at Emerson, McElligott held a variety of executive positions including vice president of Information Technology for Emerson Industrial Automation and vice president of Information Technology for Emerson Power Transmission. Previously, McElligott spent 22 years with General Electric, holding multiple information systems leadership roles, ultimately becoming CIO of supply chain for GE Aircraft Engines. McElligott was recently appointed to the board of directors at ArcBest, a publicly traded $2.6B freight transportation and logistics company and also serves as board member for Connections to Success, an organization that encourages disadvantaged men and women to achieve economic self-reliance. While in St. Louis, McElligott was a member of the board of trustees for Fontbonne University, the industry advisory council of Washington University and member on the St. Louis CIO Board. McElligott is also a member of the CIO Strategy Exchange, a small and selective multi-sponsor program for chief information officers from the most forward-looking companies. McElligott holds a Bachelor of Science degree in computer science from Kent State University and a master’s degree in business management from Xavier University.
Follow Kathy McElligott:
About McKesson: McKesson distributes medical supplies, information technology, and care management products and services.
Glenn Kramer
CTO of xCures
Glenn Kramer is an inventor, systems architect, and technology leader. At EIT in 1993 he founded one of the first Internet consultancies. When EIT was acquired by VeriFone, he architected the suite of Internet Commerce products that helped foster the sale of VeriFone to Hewlett Packard. Glenn next founded a boutique consultancy focused on solving hard Internet-based business problems while developing intellectual property for his clients. More than a decade later, he joined SRS Acquiom as Head of Development, and subsequently Chief Data Scientist, where he developed data and financial products for M&A, including the SRS Clearinghouse product and a patented, SEC-registered investment fund that used predictive analytics to get merger parties better returns for escrow funds. Glenn is currently CTO at xCures, using AI to help cancer patients get the best treatments possible when they have exhausted the standard of care options available to them. He holds 22 issued US Patents and is the author of a book published on the MIT Press, plus numerous journal and conference articles.
Follow Glenn Kramer:
About xCures: xCures is an AI-based precision oncology platform that tightly integrates cancer research and care.
Dmitry Samarsky
Chief Technology Officer of Sirnaomics
Dmitry is a recognized expert in RNAi technology and brings 15+ years of scientific, technology, and business development leadership experience at RNAi companies in the US, Asia, and Europe. Most recently he served as a Chief Scientific Officer at Silence Therapeutics (UK, Germany). Dmitry’s role is to secure Sirnaomics’ position as a leader in RNAi technology and to initiate and facilitate pharma partnering discussions.
Follow Dmitry Samarsky:
About Silence Therapeutics, Sirnaomics: Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Raphael Morozov
Chief Technology Officer of Eurofins Scientific
Raphael Morozov serves as chief technology officer at Eurofins.
Follow Raphael Morozov:
About Eurofins Scientific, WageSpot: Eurofins provides testing and support services to the pharmaceutical, food, environmental, and consumer products industries.
Ulrich Schaff
Founder & CTO of Trak
Ulrich Schaff is the CTO at Sandstone Diagnostics.
Follow Ulrich Schaff:
About Sandstone Diagnostics, Trak: Sandstone Diagnostics provides an integrated wellness technology that empowers consumers to measure, monitor, and improve their health.
Tania Timmermann
CTO of Andes
Tania Timmermann Aranis is the Chief Technology Officer of Andes.
Follow Tania Timmermann:
About Andes: Andes empowers biology to enable positive action against climate change.
Benson Fan
Founder & CTO of Calyx
Founder of BioInspira.
Follow Benson Fan:
About Calyx: Calyx harnesses biology to provide low cost and highly accurate sensors for real-time detection and analysis of air chemicals.
Karen Havenstrite
Co-Founder & CTO of Tangible Science
Karen Havenstrite, Ph.D., MBA is a Co-Founder of Tangible Science and serves as Chief Technical Officer. Karen has been with Tangible Science since inception and has led development of the HydraPEG technology from concept to commercialization. Karen received her Ph.D. in Chemical Engineering from Stanford University, where her thesis work focused on designing hydrogel materials to improve the regenerative properties of muscle stem cells; she also received her MBA from Stanford University. Karen has authorized multiple research publications, been awarded SBIR grants from the National Science Foundation, and has been recognized by the American Chemical Society as a “Talented 12” young scientist for her novel work on contact lens materials.
Follow Karen Havenstrite:
About Life Science Angels, Stanford School of Medicine, Tangible Science: Tangible Science is a developer of contact lenses designed to reduce lens discomfort in dry eye diseases.
James Ross
Chief Technology Officer of Axion BioSystems
Jim Ross was previously a product development engineer for Advanced Micro Devices and the co-founder of Nanogrip Technologies, maker of micro-scale devices used to manipulate MEMs components. He has over 7 years experience in MEMS fabrication, analog circuit design, and neural interfacing technology. During his tenure at the Microelectronics Research Center and the Laboratory for Neuroengineering, he was instrumental in producing over a dozen critically enabling technologies for the manipulation and sensing of neural tissue (many of which are patent pending). Dr. Ross received a Bachelor of Science degree in Electrical Engineering from Louisiana State University and a Doctorate in Biomedical Engineering from Georgia Tech.
Follow James Ross:
About Axion BioSystems, BioCircuit Technologies: Axion Biosystems is a life science company developing technologies that solve problems related to human heart and brain activity.
H. Lee Mosbacker
Founder & CTO of Traycer Diagnostic Systems
H. Lee Mosbacker joined CAPRICA AI as CEO in 2018. Dr. Mosbacker received his B.S. in physics from Ohio University’s Honors Tutorial College in 1999. From 2000 – 2002 he worked as a programmer analyst at Nationwide Financial developing market timing applications for mutual fund managers. In 2008, Lee received his PhD in Physics from The Ohio State University. Since 2007, Lee has been the Chief Technology Officer of Traycer Diagnostic Systems, where he has been involved in the scientific and technical aspects of growing an early-stage technology company, including grant and fund raising and the conceptualization and development of microwave and terahertz frequency detection arrays. In 2005, Lee co-founded Techriculture, a non-profit that helps inventors and scientists in early stage product ideation and prototype development through educational, networking, technical, and financial consulting.
Follow H. Lee Mosbacker:
About CAPRICA AI, HackCancerSF, OcuDoc, Syndicate app, Traycer Diagnostic Systems: Traycer Diagnostic Systems develops terahertz radiation cameras that are integrated into imaging systems.
Xiao-Jun Ma
Chief Technology Officer of Alamar Biosciences
Dr. Xiao-Jun Ma is a leader in genomic research and molecular diagnostics for personalized medicine. Applying his multi-disciplinary expertise in molecular biology, bioinformatics and statistics, Dr. Ma has a proven track record of developing molecular signatures for cancer diagnostics and identifying novel drug targets for over 14 years. Prior to joining ACD, Dr. Ma was Vice President of R&D/Biostatistics in bioTheranostics (formerly AviaraDx and Arcturus Bioscience), a bioMérieux company, where he led efforts to successfully develop several advanced molecular diagnostic tests in cancer classification and prognosis. Prior to bioTheranostics, Dr. Ma held senior bioinformatics positions at Johnson & Johnson Pharmaceutical Research Institute and Monsanto/Searle. He received his doctorate training in biochemistry at Case Western Reserve University and the University of Iowa and post-doctoral training in molecular genetics at the University of California, Los Angeles.
Follow Xiao-Jun Ma:
About Alamar Biosciences: Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time.
Bob Zuk
Founder and Chief Technology Officer of ET Healthcare
Bob Zuk, Founder and Chief Technology Officer, is respected in the life science and clinical diagnostics industries for his repeated success in integrating biochemistry with device design to provide elegantly simple solutions to challenging analytical problems. His contributions encompass diverse applications—from biosensors on the Octet platform (FortéBio) and Threshold instrument (Molecular Devices) for life science applications, to ultrasound enhanced gene delivery in myocardial and skeletal angiogenesis (Pharmasonics), to point-of-care cardiac marker tests (First Medical) and AccuLevel (Syva), one of the first commercially available, instrument-free, quantitative assay for therapeutic drug monitoring. Bob has a portfolio of more than 60 U.S. patents and pending applications. He received his B.S. in Biology from University of California, Riverside.
Follow Bob Zuk:
About ET Healthcare: ET Healthcare is an in vitro diagnostic technology company.
Richard Ellson
Chief Technology Officer of Beckman Coulter Life Sciences
Rich Ellson is the Chief Technology Officer at Beckman Coulter Life Sciences.
Follow Richard Ellson:
About Beckman Coulter Life Sciences: Beckman Coulter Life Sciences develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests.
Kensuke Numakura
CTO of Genomelink
Kensuke graduated in bioinformatics at Tohoku University, where he developed web-based applications and open-source code for the analysis of personal genomic information. He is also experienced in statistical genetics, genomic data analysis, and web development. Upon graduation, he joined P5 as head of the R&D division. He co-founded Genomelink to accelerate the transition to a society where everyone owns and are empowered by their whole genome data.
Follow Kensuke Numakura:
About Genomelink: Genomelink is a platform where people discover more with their DNA data and help businesses build, market, and do research with it.
Shekar Tippur
Chief Technology Officer of Cyclops Medtech
Follow Shekar Tippur:
About Cyclops Medtech: Medtech startup working on clinical and wearable diagnostic and rehab products for neuro vestibular disorders using eye tracking technology.
Safiyh Taghavi
CTO of Gusto Global
Safiyh Taghavi serves as the Chief Technology Officer at Gusto Global.
Follow Safiyh Taghavi:
About Gusto Global: Gusto Global is a biotherapeutics company that focuses on restoring key functionalities of a healthy microbiome.
J. Fraser Wright
Co Founder & Chief Technology Officer of Spark Therapeutics
Dr. Fraser Wright is director of the Clinical Vector Core Laboratory at The Children’s Hospital of Philadelphia, a world-class manufacturing facility that has designed, manufactured, characterized and certified recombinant adeno-associated viruses (AAV) and lentiviruses (rLenti) for human gene therapy trials. He is also an associate professor of pathology and laboratory medicine at the University of Pennsylvania. Fraser has led efforts in basic research, process and analytical methods development, and GMP manufacturing and quality systems supporting translational research. He has overseen investigational product chemistry, manufacturing and controls for gene therapy vectors administered to more than 100 human subjects in 12 clinical studies. His primary research interests focus on the development and clinical translation of gene therapy vectors with the goal of achieving effective new treatments for serious human diseases. With basic training in biochemistry, immunology and virology, Fraser has been engaged for more than 20 years in the development of viral vector-based new biologic products in both industry and academic settings, and previously served as director of development and clinical manufacturing at Avigen, Inc. He received his B.S. and Ph.D. in biochemistry from the University of Toronto.
Follow J. Fraser Wright:
About Sio Gene Therapies, Spark Therapeutics: Spark Therapeutics is focused on the development of gene therapy.
Dan Zulla
CTO of WaveAcid Inc.
Hacker; Serial Entrepreneur; Security Engineer
Follow Dan Zulla:
About Atos, WaveAcid Inc.: Biotechnology; Chemical Synthesis; Handheld Portable Device; Artificial Intelligence; Machine Learning
Jessie Ho
Cofounder & CTO of Chai
Jessie Ho is the COO and cofounder of Chai. Prior to Chai she was an engineering manager at CellASIC, and led instrument design teams at EMD Millipore and Accel Biotech. Jessie holds several patents in microfluidics and is a graduate of MIT.
Follow Jessie Ho:
About Chai: Chai develops products that make the core biological technologies more useful and readily available to all.
Nick Goeden
Co-founder and Chief Technology Officer of Capsida
Nick Goeden is the Co-founder and Chief Technology Officer at Capsida Biotherapeutics. Prior to that, he was a Postdoctoral Fellow at Caltech.
Follow Nick Goeden:
About Capsida: Capsida is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders.
Steven A. Soper
CTO of BioFluidica
Dr. Steven A. Soper founded Biofluidica in order to develop new technologies to be used in the medical diagnostic, pathogen detection, and personalized medicine spaces. He is a worldwide recognized pioneer in the development of diagnostic platforms with over 12 years of experiences in the CTC research area along with being the author of five patents currently licensed by BioFluidica. He has over 310 peer-reviewed publications with an h-index of 56. In addition, he has generated over $60M in competitive research funding over his career with most of this funding focused on developing new technologies for in vitro diagnostics. Dr. Soper is currently a Professor in Biomedical Engineering and Chemistry at UNC-CH. He is also Director of a new Center on the UNC-CH campus; Center for BioModular Multi-scale Systems for Precision Medicine, which is focused on developing new tools for the molecular analysis of circulating biomarkers.
Follow Steven A. Soper:
About BioFluidica, University of North Carolina at Chapel Hill: BioFluidica is a biotechnology company that has developed a diagnostic platform.
Sergei Gryaznov
CTO of Exicure
Sergei Gryaznov is the Chief Scientific Officer at MAIA Biotechnology.
Follow Sergei Gryaznov:
About Exicure, MAIA Biotechnology: Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.
Sanford Boye
Founder and Chief Technology Officer of Atsena Therapeutics
Sanford Boye is the Founder and Chief Technology Officer at Atsena Therapeutics.
Follow Sanford Boye:
About Atsena Therapeutics: Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
Chris A. Rhodes
Chief Technology Officer & Co-Founder of Sensulin
Chief Technology Officer of Sensulin.
Follow Chris A. Rhodes:
About Baywind Bioventures, Drug Delivery Experts, Sensulin: Sensulin is a diabetes drug discovery company developing a once-a-day glucose-responsive insulin.
Heinrich Röder
CTO of Biodesix
Heinrich Röder is a company founder and author or co-author of more than 100 publications/talks in theoretical physics and computational sciences. Heinrich Röder obtained his D.Phil at Oxford University, and went on to become an eminent theoretical physicist with positions at University of Hanover and Bayreuth (Germany) and Los Alamos National Laboratory. He has led projects involving the diagonalization of gigadimensional matrices, has done pioneering work in the microscopic mechanisms of colossal magneto resistive perovskites, and initiated the first use of large-scale inverse problem techniques in the analysis of neutron scattering data. Recruited from Los Alamos, Heinrich Röder serves as Biodesix’ CTO, leading the Research and Development side of the Company and designing functionality for next generation products and services. Heinrich Röder is a Rhodes Scholar.
Follow Heinrich Röder:
About Biodesix: Biodesix is a molecular diagnostics company engaged in the development of innovative products for personalizing medicine.
Ouwei Wang
Co-Founder and Chief Technology Officer of Pow.bio
Ouwei Wang is the Co-Founder and Chief Technology Officer at Pow.bio.
Follow Ouwei Wang:
About Pow.bio: Pow.bio provides a genetically engineered solution for fermentation scientists.
Michael Felix
CTO & Co-Founder of Slope.io
Michael Felix is the Co-founder & CTO at Slope.io
Follow Michael Felix:
About Slope.io: Slope.io is a provider of a healthcare software designed to offer an easy way to prevent inventory outages.
Nick Ouzounov
Co-Founder and CTO of Geltor
Follow Nick Ouzounov:
About Geltor: Geltor is a bio-design company that makes proteins used in beauty, food, & beverage products like collagen and elastin, but without animals.
John Hoekman
Co-Founder, Chief Scientific Officer, Chief Technology, and Development Officer of Impel NeuroPharma
John Hoekman has focused on nasal drug delivery with an emphasis on delivery targeting the central nervous system using innovative device design and drug delivery systems. His research experience includes working with Dr. William Frey, one of the pioneers of nose-to-brain drug delivery, and Dr. Rodney Ho at the University of Washington. His unique background in both Physics and Pharmaceutics led to the development of Impel NeuroPharma’s core nasal delivery technology, the Pressurized Olfactory Delivery (POD) devices, of which he is co-inventor.
Follow John Hoekman:
About Impel NeuroPharma: Impel NeuroPharma is a medical device company that develops a novel drug delivery device that uses direct nose-to-brain delivery.
John S. Oliver
Chief Technology Officer & Chief Scientific Officer of Nabsys
John Oliver is the Chief Scientific Officer & CTO at Nabsys.
Follow John S. Oliver:
About Nabsys: Nabsys is a life sciences company focused on the development of solid-state, single-molecule positional sequencing technology.
Adrian Schreyer
Chief Technology Officer of Exscientia
Adrian is an interdisciplinary researcher with a broad background in computational approaches to drug discovery. He also holds a PhD from the University of Cambridge, where he studied under the supervision of Professor Sir Tom Blundell FRS FMedSci.
Follow Adrian Schreyer:
About Exscientia: Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
Ankit Gupta
Co-Founder, CTO of Reverie Labs
Ankit Gupta is the CTO and Co-Founder at Reverie Labs. He is a graduate of Harvard University.
Follow Ankit Gupta:
About Reverie Labs: Reverie Labs is a machine learning-driven pharma company.
Zhitong Liu
Co-Founder and CTO of Paragon Genomics
Zhitong Liu is a Co-Founder and CTO at Paragon Genomics.
Follow Zhitong Liu:
About Paragon Genomics: A targeted DNA sequencing company
Randy Ringold
President, CTO of VDI Laboratory
Randy is the Founder and President of VDI Laboratory, LLC, a company dedicated to the development and commercialization of innovative biomarkers for the companion animal market. Randy has a 30+ year tenure in the IVD industry and has held senior level management positions with Baxter Healthcare and Sysmex International. Prior to forming VDI, Randy was Vice President, WW Sales and Marketing at Nichols Institute, a division of Quest Diagnostics (NYSE:DGX), leading to expand the global presence of esoteric testing throughout the US, Europe, Japan, and Latin America. Mr. Ringold has a BSc and MBA from California State University, Northridge and is a licensed Clinical Laboratory Scientist. Randy has developed numerous patents in the field of laboratory diagnostics. His professional interests include sepsis, endocrinology and the use of computers in contextual diagnostics.
Follow Randy Ringold:
About Glycominds, Kepler Diagnostics, VDI Laboratory: VDI Laboratory is a specialty reference lab for companion animals. VDI specializes in converting human blood tests for use in pets. .
Justin Sanchez
CTO and Co-Founder of Terra Vera
Justin Cofounded Terra Vera corporation in April of 2020, bringing over 14 years of experience in novel on-demand chemistry applications at MIOX and DeNora. A serial entrepreneur with a multidisciplinary skill set in Operations and Engineering, Justin is committed to Terra Vera’s goal of replacing harmful pesticides with safer, greener, and cleaner alternatives. Justin has undergraduate and graduate degrees from the Massachusetts Institute of Technology, including a BS and MS in Materials Science and an MBA from the Sloan School of Management. He attended MIT’s Leaders for Global Operations Program
Follow Justin Sanchez:
About MIOX, Terra Vera: A safe, platform technology provider that enables clients to control their anti-microbial supply chain
Christine Santos
CTO of Manus Bio
Follow Christine Santos:
About Manus Bio: Manus Bio makes nature accessible and affordable for a growing society.
Natalie Wisniewski
Co-Founder & CTO of Profusa
Natalie conceived the technical approach behind Profusa. Together with Bill, she built the company road map, enlisted top talent and secured start-up funding. Natalie leads Profusa’s technology development efforts and the grants program, which has secured $10M of DARPA and NIH funds. Natalie is the co-inventor of Profusa’s tissue-integrating biosensor technology and optical reader. Winner of the NIH Transformative Research Award, she is a recognized leader in understanding the body’s reaction to foreign materials and the design of bioengineered sensors. In addition to her science career, she was a business consultant at McKinsey & Company and a consumer products developer at Kimberly-Clark. She has nearly two decades of regulatory, clinical and technical consulting experience in the medical device industry. Natalie earned a B.S. in Chemical Engineering from Purdue University, and a Ph.D. in Biomedical Engineering from Duke University in collaboration with the Karolinska Institute where she developed her passion for continuous monitoring of body chemistries.
Follow Natalie Wisniewski:
About Profusa: PROFUSA is a medical devices company creating tissue-integrated sensors for chronic disease management and healthy living.
Nicolas G Loebel
President & Chief Technology Officer of Ondine Biomedical
Dr. Loebel serves as President and Chief Technology Officer to the Company, specializing in product research and development, photochemistry, systems integration, and cross-functional team building. His research focus has centered on novel photochemistries, rheological modeling of periodontal disease and tooth mobility, fiber optic waveguide propagation theory, evanescent coupling and the applications of optical fibers to interferometric sensors. He has experience in dental and medical product development and manufacturing, corporate management and business development in public and private market environments. He has authored numerous publications and patents and lectures regularly on antimicrobial photodynamics around the world.
Follow Nicolas G Loebel:
About Ondine Biomedical: Ondine Biomedical develops non-antibiotic, anti-infective therapies for a broad spectrum of bacterial, viral, and fungal infections.
